| Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy. | |
| | |
MedLine Citation:
|
PMID: 20564078 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: There is a crucial need for better therapeutic approaches for the treatment of Ewing sarcoma (EWS). Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in EWS cells in vitro. However, in vivo, acquired resistance to TRAIL is a major limiting factor. Platelet-derived growth factor receptor-beta (PDGFR-beta) is highly expressed on EWS cells. Thus, the authors evaluated whether PDGFR-beta blockade could sensitize EWS cells to TRAIL-induced apoptosis in vitro and in vivo. METHODS: The effect of combined imatinib mesylate (Gleevec) and TRAIL on EWS cell growth and apoptosis was tested in vitro. Stable PDGFR-beta knockdown in EWS cells was achieved by short-hairpin RNA transduction, and TRAIL sensitivity of these cells was measured. Expression of death receptors was measured by fluorescence-activated cell-sorting (FACS) analysis, and caspase 8 activity was evaluated by Western blot analysis. An orthotopic human xenograft model of EWS growth and spontaneous metastasis in nude mice was used to assess the in vivo affect of combined imatinib mesylate and TRAIL. RESULTS: Imatinib mesylate induced a significant TRAIL proapoptotic effect in EWS cells in vitro. Specific PDGFR-beta silencing in EWS cells enhanced the effects of TRAIL, possibly through an increase in the expression of death receptors 4 and 5. The combination of imatinib mesylate and TRAIL significantly inhibited the growth of primary tumors and decreased the incidence of spontaneous EWS pulmonary metastasis compared with either drug alone. CONCLUSIONS: PDGFR-beta blockade combined with TRAIL resulted in antihuman EWS activity in vitro and in vivo, suggesting the possibility that combining these treatments will improve anti-EWS therapy. |
| | |
Authors:
|
Yongxin Wang; Deendayal Mandal; Suizhau Wang; Eugenie S Kleinerman; Raphael E Pollock; Dina Lev; Andrea Hayes-Jordan |
Related Documents
:
|
17938258 - Formyl peptide receptor-like 1 mediated endogenous trail gene expression with tumoricid... 12883638 - Identification of interaction between pai-2 and irf-3. 16513168 - Prostate-apoptosis-response-gene-4 increases sensitivity to trail-induced apoptosis. 19449148 - Egfr-targeted diphtheria toxin stimulates trail killing of glioblastoma cells by deplet... 1840698 - A heparin-binding growth factor secreted by macrophage-like cells that is related to egf. 7523318 - Myeloid cell proliferation stimulated by steel factor is pertussis toxin sensitive and ... |
Publication Detail:
|
Type: Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Cancer Volume: 116 ISSN: 0008-543X ISO Abbreviation: Cancer Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-08-10 Completed Date: 2010-10-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 3892-902 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright (c) 2010 American Cancer Society. |
Affiliation:
|
Department of Pediatrics-Research, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Humans Mice Mice, Nude Neoplasm Metastasis / prevention & control Piperazines / administration & dosage* Protein Kinase Inhibitors / administration & dosage* Pyrimidines / administration & dosage* Receptor, Platelet-Derived Growth Factor beta / antagonists & inhibitors* Sarcoma, Ewing's / drug therapy*, pathology TNF-Related Apoptosis-Inducing Ligand / administration & dosage* Tumor Cells, Cultured |
| Chemical | |
Reg. No./Substance:
|
0/Piperazines; 0/Protein Kinase Inhibitors; 0/Pyrimidines; 0/TNF-Related Apoptosis-Inducing Ligand; 152459-95-5/imatinib; EC 2.7.10.1/Receptor, Platelet-Derived Growth Factor beta |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: How might VA-Medicare differences inform the delivery of end-of-life cancer care?
Next Document: Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refract...